Search Result For: mounjaro
Date: 2025/03/17 - 15:01
Mounjaro can boost weight loss in people without diabetes
People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label treatment, according to a new study funded by pharmaceutical company Eli Lilly.
Date: 2025/02/10 - 21:00
Review links 3 potentially-blinding eye conditions to GLP-1 drugs like Ozempic
A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.
Date: 2025/01/22 - 00:32
GLP-1 Drugs Benefit Brain and Heart Health, but May Cause Kidney, GI Issues
A large study published in Nature Medicine reviewed the effects of GLP-1 drugs like Ozempic and Mounjaro on 175 different health outcomes. The findings show benefits for brain and heart health, but risks of developing gastrointestinal, kidney, and pancreatic issues.
Date: 2025/01/21 - 20:31
GLP-1 drugs linked to lower dementia risk, higher risk of kidney, stomach issues
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, addiction, heart disease, and gastrointestinal problems, among others.
Date: 2024/12/06 - 00:00
Zepbound Leads to More Weight Loss Than Wegovy in Head-to-Head Clinical Trial
Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Results from a clinical trial show 20% of participants who took Zepbound achieved significant weight loss compared to nearly 14% of participants who took Wegovy.
